GlassScriptPhysician profile
Keta Vaidya
NPI 1891923256
$9,279.34
in general payments reported to CMS, 2019-2025
43 companies · $1,932 in 2025
The $1,932 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $693 · 2020: $204 · 2021: $987 · 2022: $1,705 · 2023: $2,030 · 2024: $1,730 · 2025: $1,932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,560 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,559.90 |
| Education | $131.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,159.67 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Janssen Biotech, INC. | $1,285.52 | 2019-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $984.05 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Pfizer INC. | $706.43 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $512.31 | 2019-2025 | Entyvio |
| Gilead Sciences, INC. | $266.27 | 2019-2025 | |
| Qol Medical, LLC | $221.69 | 2019-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $181.50 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $154.28 | 2019-2023 | Linzess |
| Ferring Pharmaceuticals INC. | $147.57 | 2021-2025 | Rebyota |
| Ardelyx, INC. | $135.57 | 2023-2025 | Ibsrela |
| Celgene Corporation | $127.19 | 2021-2023 | Zeposia |
| Merck Sharp & Dohme LLC | $112.97 | 2019-2024 | Dificid |
| Genzyme Corporation | $103.60 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $100.91 | 2022-2024 | Ocaliva |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $85.40 | 2025 | Voquezna |
| Celltrion USA INC. | $84.91 | 2023-2025 | Zymfentra, Vegzelma, Yuflyma |
| Madrigal Pharmaceuticals | $80.60 | 2025 | Rezdiffra |
| Aimmune Therapeutics, INC. | $79.01 | 2023-2025 | Zenpep, Vowst |
| Nestle Healthcare Nutrition INC. | $69.64 | 2021-2023 | |
| Evoke Pharma, INC. | $67.76 | 2022-2024 | Gimoti |
| Braintree Laboratories, INC. | $64.31 | 2019-2023 | Sutab |
| Ipsen Biopharmaceuticals, INC | $54.83 | 2025 | Iqirvo |
| Lilly USA, LLC | $52.20 | 2023-2025 | Omvoh |
| Redhill Biopharma INC. | $45.24 | 2022 | |
| Ucb, INC. | $36.72 | 2019-2020 | |
| Conmed Corporation | $35.18 | 2025 | Conmed Polypectomy |
| Boston Scientific Corporation | $32.10 | 2021-2022 | |
| Exact Sciences Corporation | $31.89 | 2023-2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $29.77 | 2025 | Wegovy |
| Mallinckrodt Hospital Products INC. | $24.51 | 2024 | Terlivaz |
| Allergan, INC. | $22.66 | 2019 | |
| Organon LLC | $21.06 | 2024 | |
| Biocon Biologics INC | $20.26 | 2025 | Yesintek |
| Concordia Pharmaceuticals INC. | $20.08 | 2019 | |
| Intra-Sana Laboratories | $19.73 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Axonics, INC. | $18.87 | 2024 | Axonics |
| Laborie Medical Technologies Corp. | $14.65 | 2024 | |
| Fresenius Kabi USA, LLC | $14.36 | 2024 | Idacio |
| E.R. Squibb & Sons, L.L.C. | $13.68 | 2022 | |
| Dynavax Technologies Corporation | $13.55 | 2021 | |
| Mylan Institutional INC. | $13.44 | 2023 | Hulio |
| Shire North American Group INC | $13.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keta Vaidya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.